<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82248">
  <stage>Registered</stage>
  <submitdate>30/08/2007</submitdate>
  <approvaldate>10/09/2007</approvaldate>
  <actrnumber>ACTRN12607000455460</actrnumber>
  <trial_identification>
    <studytitle>Fish oils in chronic kidney disease</studytitle>
    <scientifictitle>A 12 week intervention examining the effect of fish oil on appetite, inflammatory markers and nutritional parameters in dialysis patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All participants are given a fish oil supplement containing 2g Eicosapentaenoic Acid (EPA) per day for 12 weeks (capsules or oil, participants choice). All outcomes (appetite, inflammatory, nutritional, quality of life) are measured at baseline and 12 weeks. Appetite also measured at wk 4 and wk 12. Participants consent to pre-baseline data being used as historical control.</interventions>
    <comparator>The control will be historial control. The consent process will involve participants consenting that data from routine care can be used in analysis. Data from 12 weeks prior to baseline accessed from medical records.</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Appetite, measured by: 1) Rating appetite on a Likert scale 2) Rating appetite on a visual analog scale, plus 3) blood markers (leptin, ghrelin, peptide YY, glucopeptide-1).</outcome>
      <timepoint>Pre-baseline, baseline, week4, week 8 and week 12.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Inflammation, measured by the following markers: 1) Interleukin 6, 2) C-reactive protein 3) Adhesion molecules 4) White cell count.</outcome>
      <timepoint>Prebaseline, baseline and week 12.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life, measured by the Kidney Disease Quality of Life questionnaire.</outcome>
      <timepoint>Baseline and week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dietary Intake, measured by 3-day food record kept by the participants which will later be reviewed by the trial's research staff and analysed using Foodworks ver 3.0 (Xyris software).</outcome>
      <timepoint>Prebaseline, baseline and week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult chronic kidney disease patients aged &gt; 18 years who have been receiving hemodialysis for &gt; 3 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Taking a fish oil supplement providing &gt; 500 mg/day, aged &lt; 18 years, on hemodialysis &lt; 3 months, presence of emotional, cognitive or language limitations impairing their ability to provide informed consent or follow study instructions (where a carer or translator is not available).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>4066</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Queensland University of Technology</primarysponsorname>
    <primarysponsoraddress>Faculty of Health
Kelvin Grove Campus
Victoria Park Road
Kelvin Grove QLD 4059</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Queensland University of Technology</fundingname>
      <fundingaddress>Faculty of Health
Kelvin Grove Campus
Victoria Park Road
Kelvin Grove QLD 4059</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>The Wesley Hospital</sponsorname>
      <sponsoraddress>451 Coronation Drive
Auchenflower QLD 4066</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to explore the effect of EPA (fish oil) on appetite, inflammatory markers and nutritional parameters in dialysis patients. Previous research has shown anti-inflammatory effects from fish oil and there is some evidence to indicate that poor appetite may be associated with inflammation. We aim to explore this relationship.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland University of Technology Human Research Ethics Committee</ethicname>
      <ethicaddress>GPO Box 2434
Brisbane QLD 4001</ethicaddress>
      <ethicapprovaldate>18/12/2006</ethicapprovaldate>
      <hrec>0600000589</hrec>
      <ethicsubmitdate>12/09/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rachel Zabel</name>
      <address>Institute of Health and Biomedical Innovation (IHBI)
Cnr Musk Ave and Blamey Street
Kelvin Grove QLD 4059</address>
      <phone>+61 7 31386134</phone>
      <fax />
      <email>r.zabel@qut.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rachel Zabel</name>
      <address>Institute of Health and Biomedical Innovation (IHBI)
Cnr Musk Ave and Blamey Street
Kelvin Grove QLD 4059</address>
      <phone>+61 7 31386134</phone>
      <fax />
      <email>r.zabel@qut.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rachel Zabel</name>
      <address>Institute of Health and Biomedical Innovation (IHBI)
Cnr Musk Ave and Blamey Street
Kelvin Grove QLD 4059</address>
      <phone>+61 7 31386134</phone>
      <fax />
      <email>r.zabel@qut.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>